Inflammaging: How Chronic Low-Grade Inflammation Accelerates Aging (and What to Do About It)

At a Glance

Every patient who walks into my integrative clinic asking about longevity eventually encounters the same concept: their blood is quietly on fire, and they have no idea. The term is inflammaging — a portmanteau coined by Italian immunologist Claudio Franceschi in 2000 that captures something the mainstream medical system largely ignores until organs start failing.

Inflammaging describes a chronic, low-grade, sterile inflammatory state that accumulates with age. Unlike the acute inflammation you experience when you sprain an ankle — which resolves in days — inflammaging smolders for decades. It doesn’t cause obvious pain or fever. But it relentlessly erodes vascular endothelium, prunes synaptic connections, degrades insulin signaling, and creates a permissive environment for oncogenesis.

The result: nearly every major age-associated disease — Alzheimer’s, cardiovascular disease, type 2 diabetes, sarcopenia, frailty — has inflammaging woven into its pathophysiology. Understanding and measuring it is, in my clinical view, one of the most important steps any serious longevity patient can take.

The Biology of Inflammaging: What’s Actually Happening

To appreciate why inflammaging is distinct from ordinary inflammation, you need to understand its molecular origins. Several converging processes feed the flame.

Senescent Cells and the SASP

As cells accumulate DNA damage, telomere shortening, or oncogenic stress, they enter a state of permanent cell-cycle arrest called senescence. Rather than dying cleanly (apoptosis), senescent cells persist and actively secrete a cocktail of pro-inflammatory cytokines, chemokines, proteases, and growth factors — collectively termed the Senescence-Associated Secretory Phenotype (SASP).

SASP components include IL-6, IL-8, IL-1β, MCP-1, and matrix metalloproteinases (MMPs). In small numbers in young tissue, senescent cells serve beneficial roles in wound healing and tumor suppression. But with aging, accumulation overwhelms this utility. Studies in mice show that selectively eliminating senescent cells (using senolytic drugs like dasatinib + quercetin) extends healthspan and reduces multiple markers of age-related pathology.

In my patients, high IL-6 with relatively normal CRP often points to SASP as a dominant driver — a pattern I look for specifically when evaluating the inflammaging burden.

Mitochondrial Dysfunction and DAMPs

Aging mitochondria leak damage-associated molecular patterns (DAMPs) — most notably mitochondrial DNA (mtDNA), which resembles bacterial DNA and potently activates the cGAS-STING innate immune pathway. This pathway, evolved to detect viral and bacterial invasion, interprets aging mitochondria as a pathogenic threat and fires off NF-κB-driven inflammatory transcription.

Mitochondrial uncoupling, declining NAD+ levels, and impaired mitophagy all amplify this signal. This is one of the mechanistic reasons why NAD+ repletion strategies (NMN, NR, or IV NAD+) appear to reduce inflammatory markers in early clinical studies — restoring NAD+ improves mitochondrial quality control and attenuates DAMP release.

Gut Dysbiosis and Leaky Gut (“Inflammaging from Below”)

The intestinal barrier deteriorates with age through multiple mechanisms: reduced tight junction protein expression, altered mucus layer composition, and shifts in microbiome community structure. This permits translocation of lipopolysaccharide (LPS) from gram-negative gut bacteria into the systemic circulation — a phenomenon measurable as elevated serum LPS-binding protein (LBP).

Circulating LPS activates Toll-like receptor 4 (TLR4) on macrophages and endothelial cells throughout the body, driving sustained NF-κB activation. Franceschi himself termed this contribution “inflammaging from below.” In practice, I routinely see a correlation between high LBP, elevated zonulin (marker of intestinal permeability), and blunted immune aging markers — fixing the gut meaningfully shifts the inflammatory profile.

Visceral Adipose Tissue as an Endocrine Organ

Visceral fat is not metabolically inert — it functions as an inflammatory endocrine organ. Adipocytes and embedded macrophages (crown-like structures in hypertrophied fat) secrete TNF-α, IL-6, IL-1β, and leptin while suppressing the anti-inflammatory cytokine adiponectin. As visceral fat accumulates with age, so does the ambient cytokine load.

The critical clinical point: a patient can appear lean by BMI but carry significant visceral fat measurable only by DEXA or MRI. Waist circumference (>94 cm men, >80 cm women in European standards) provides a quick clinical screen, but imaging is definitive.

Key Biomarkers: How We Measure Inflammaging

Clinically, I use a panel of biomarkers to characterize a patient’s inflammaging burden. No single marker is sufficient.

High-Sensitivity CRP (hsCRP)

The most accessible marker. Optimal: <0.5 mg/L. Values 1–3 mg/L represent intermediate risk for cardiovascular events; >3 mg/L indicates elevated risk. Importantly, hsCRP is a downstream acute-phase reactant — it can be normal even with significant IL-6 elevation if the liver’s acute-phase response is blunted. Never rely on hsCRP alone.

Interleukin-6 (IL-6)

IL-6 is perhaps the most central cytokine in inflammaging. It drives acute-phase protein production (including CRP and fibrinogen), promotes the T helper 17 / Treg imbalance associated with aging, and directly damages the hippocampus at sustained elevated levels. Optimal: <2 pg/mL. Values >5 pg/mL in the absence of acute illness warrant investigation.

TNF-α (Tumor Necrosis Factor Alpha)

A key mediator of insulin resistance and muscle catabolism in aging. Elevated TNF-α accelerates sarcopenia by activating ubiquitin-proteasome degradation pathways in skeletal muscle. Optimal: <8 pg/mL.

GDF-15 (Growth Differentiation Factor 15)

An emerging longevity biomarker. GDF-15 rises sharply with mitochondrial stress, inflammation, and cancer. It correlates strongly with all-cause mortality in longitudinal cohorts. The GDF-15 range in young adults is typically 200–1,000 pg/mL; values >1,800 pg/mL in non-cancer patients often reflect significant inflammaging.

Additional Useful Markers

• Fibrinogen: Acute-phase protein; elevated in chronic inflammation and cardiovascular risk (>350 mg/dL warrants attention)
• Ferritin: Can reflect iron-driven oxidative inflammation when markedly elevated (>300 ng/mL in men, >150 in women without acute illness)
• Homocysteine: Pro-inflammatory at elevated levels; methylation insufficiency raises both homocysteine and downstream inflammatory signaling
• Omega-6:Omega-3 ratio: Ideally <4:1; typical Western values of 15:1–20:1 drive arachidonic acid cascade–mediated inflammation

Evidence-Based Interventions for Inflammaging

Managing inflammaging requires addressing its upstream drivers, not just suppressing downstream cytokines. Here is what the evidence supports.

Senolytics: Clearing Senescent Cells

The most direct approach to SASP-driven inflammaging is senolytic therapy — drugs or compounds that selectively clear senescent cells.

Quercetin + Dasatinib (D+Q): The original clinical senolytic combination. Quercetin (500–1,000 mg) acts on BCL-2 family antiapoptotic proteins that senescent cells depend on for survival. The D+Q combination reduced senescent cell burden in adipose tissue and improved physical function in a Mayo Clinic pilot RCT (Kirkland et al., 2019). Typical protocols use intermittent pulsing — e.g., 2–3 consecutive days per month — rather than daily dosing.

Fisetin: A flavonoid with strong senolytic activity in rodent models and emerging human data. More bioavailable than quercetin in some formulations. A study in older adults showed reduction in senescent T cells and plasma SASP factors with 20 mg/kg/day pulsed dosing.

The clinical reality: senolytics represent the most mechanistically targeted anti-inflammaging approach available today without a prescription (except dasatinib, which requires one). The downside: human longevity trial data remain limited; we’re extrapolating significantly from animal data.

Dietary Interventions

Diet remains the most consistently validated inflammaging intervention across all evidence tiers.

Mediterranean diet: Associated with 25–30% lower IL-6 and CRP in meta-analyses. Rich in polyphenols (olive oil, berries, legumes), omega-3 fatty acids (oily fish), and fiber (supporting gut barrier integrity). The PREDIMED trial demonstrated cardiovascular event reduction that correlates with inflammaging biomarker improvement.

Caloric restriction and intermittent fasting: Activate AMPK and SIRT1 pathways, suppress mTOR, reduce visceral adiposity, and directly lower NF-κB activity. A 12% caloric restriction over 2 years in the CALERIE trial reduced CRP by 33% and TNF-α by 21% in healthy adults.

Ultra-processed food elimination: Ultra-processed foods (emulsifiers, refined seed oils, additives) disrupt gut microbiome diversity and increase intestinal permeability. A single 4-week elimination trial in healthy volunteers showed measurable improvement in inflammatory markers — an effect I consistently observe clinically.

Omega-3 Fatty Acids

EPA and DHA compete with arachidonic acid for COX and LOX enzyme activity, shifting eicosanoid production from pro-inflammatory prostaglandin E2 toward anti-inflammatory resolvins and protectins. Meta-analyses support dose-dependent reduction in IL-6 and CRP.

Clinical dosing: 2–4 g/day of combined EPA+DHA, ideally with a meal. At the higher end of this range, triglyceride reduction (25–30%) is an additional benefit. Monitoring omega-6:omega-3 ratio is preferable to guessing at dose sufficiency.

NAD+ Repletion

Declining NAD+ with age impairs mitochondrial function, reduces SIRT1/SIRT3 activity (which normally suppress NF-κB), and increases cGAS-STING activation from mitochondrial DAMPs. NMN and NR supplementation partially restore NAD+ levels in humans, and early clinical data suggest modest reductions in inflammatory markers.

IV NAD+ delivers far higher acute plasma levels than oral supplementation. In my clinical experience, patients with high GDF-15 and IL-6 attributable to mitochondrial dysfunction respond particularly well to IV NAD+ protocols combined with oral NMN maintenance.

Targeted Nutraceuticals

Several compounds have robust evidence for NF-κB suppression and inflammaging mitigation:

• Curcumin (liposomal or BCM-95 formulation): Directly inhibits NF-κB and COX-2; reduces CRP at 1–2 g/day in multiple RCTs
• Resveratrol: Activates SIRT1, reduces NF-κB signaling; best evidence at 150–500 mg/day
• Berberine: Activates AMPK (mimicking caloric restriction), reduces IL-6 and TNF-α, improves insulin sensitivity; 500 mg 2–3× daily
• Magnesium: Deficiency drives NF-κB activation; optimal serum levels >0.85 mmol/L; 300–400 mg/day supplementation widely indicated
• Sulforaphane (from broccoli sprout extract): Activates Nrf2, the master antioxidant transcription factor; reduces 8-OHdG (oxidative DNA damage) and NF-κB activity

Exercise

Acute exercise is transiently pro-inflammatory; chronic exercise is potently anti-inflammatory. Regular moderate-intensity aerobic exercise reduces circulating IL-6, TNF-α, and CRP through multiple mechanisms: visceral fat reduction, IL-15 and IL-10 myokine release, and improved mitochondrial quality control via PGC-1α signaling.

Zone 2 training (moderate intensity sustainable for 45–60 minutes) appears optimal for mitochondrial density improvements. Resistance training is non-negotiable for sarcopenia prevention — sarcopenic muscle itself becomes an inflammatory source through damaged myofibers and local macrophage infiltration.

My Clinical Protocol for Inflammaging

When a patient presents with elevated IL-6, hsCRP, or GDF-15 in the absence of acute illness or active cancer, my starting framework is:

1. Identify drivers: Gut panel (GI-MAP or equivalent), organic acids test, heavy metal screen, visceral fat quantification, sleep quality assessment
2. Fix the gut first: Targeted dysbiosis treatment, gut-healing peptides (KPV, BPC-157 if indicated), probiotics selected for IL-10–inducing strains
3. Layer anti-inflammatory nutrition: Mediterranean framework, eliminate ultra-processed foods, optimize omega-6:omega-3 ratio
4. Add evidence-based nutraceuticals: Omega-3 (3–4 g EPA+DHA), curcumin (1.5 g BCM-95), magnesium (400 mg glycinate), sulforaphane
5. Consider senolytic pulsing in patients >50 with high SASP markers: quercetin + fisetin for 2–3 consecutive days monthly
6. Address mitochondrial dysfunction: NAD+ repletion strategy individualized to response
7. Optimize sleep and exercise: Chronic sleep deprivation independently elevates IL-6 by >40%; Zone 2 training 3–4×/week minimum
8. Re-check biomarkers at 12 weeks: IL-6, hsCRP, GDF-15 minimum panel

The goal is not to suppress inflammation completely — baseline immune surveillance requires some inflammatory capacity. The goal is to shift from the chronic smoldering of inflammaging to the clean, responsive, resolving inflammation of a younger immune phenotype.

Related Articles

• Senolytics: The Science of Clearing Senescent Cells
• NAD+ IV Therapy: What to Expect and Who Benefits
• Gut-Brain Axis: How the Microbiome Drives Systemic Healing
• Quercetin as a Senolytic: Dosing, Evidence, and Protocols
• Omega-3 Fatty Acids and Inflammation: Clinical Evidence

References

1. Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging: An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-254. PMID: 10911963

2. Kirkland JL, Tchkonia T, Zhu Y, Niedernhofer LJ, Robbins PD. The clinical potential of senolytic drugs. J Am Geriatr Soc. 2017;65(10):2297-2301. PMID: 28869295

3. Ferrucci L, Fabbri E. Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505-522. PMID: 30065258

4. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34. PMID: 29897866

5. Ravussin E, Redman LM, Rochon J, et al. A 2-year randomized controlled trial of human caloric restriction: Feasibility and effects on predictors of health span and longevity. J Gerontol A Biol Sci Med Sci. 2015;70(9):1097-1104. PMID: 26187991

6. Calder PC. Omega-3 fatty acids and inflammatory processes: From molecules to man. Biochem Soc Trans. 2017;45(5):1105-1115. PMID: 28900017

7. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: A new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-590. PMID: 30046148